In VivoBiopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede
In VivoBiopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu